China
Deal focus: CDH plays Asia wellness card
CDH Investments turned The Better Health Company from a New Zealand-only player into a brand with regional recognition. COVID-19 proved a minor obstacle to an ultimately successful trade sale
Legend leads $150m Series E for China CRO ClinChoice
US and China-based clinical contract research organization (CRO) company ClinChoice has raised a USD 150m Series E round led by Legend Capital.
Sequoia raises $8.8b for China funds
Sequoia Capital has hit the hard cap on each of the four funds in its latest China vintage, accumulating USD 8.8bn for deployment in seed through late-growth rounds.
China IC software player raises $81m
Semi-Tech, a China-based semiconductor manufacturing software provider, has raised CNY 540m (USD 81m) across two rounds - the second extended tranche of a Series A and a Series B.
Sequoia, Dayone back China solid state battery developer
China-based Enpower Greentech, which claims to be a pioneer in next-generation all-solid-state batteries (ASSBs), has raised more than USD 20m in an extended Series A round led by Sequoia Capital China and Dayone Capital.
CDH exits New Zealand supplements brand to Nestle
CDH Investments has agreed to sell New Zealand-based supplements manufacturer The Better Health Company (TBHC) to Nestlé Health Science for an undisclosed sum.
China biotech: End of the boom
PE investment in China biotech has collapsed amid failed IPO processes and disputed valuations. Pockets of activity remain, though questions around commercialisation have yet to be answered
Portfolio: Welkin Capital and Shawya
Shawya is a fast-rising Chinese direct-to-consumer brand that takes a technology-driven approach to skincare. Welkin Capital is helping it address growing pains around talent and omnichannel capabilities
KKR's Greater China head transitions to advisor role
Paul Yang, KKR’s Greater China head, is moving to an advisory role as the private equity firm looks to appoint a replacement based full-time in mainland China.
Fund focus: Re-ups underpin FountainVest's Fund IV close
Despite headwinds that have afflicted all China-focused managers, FountainVest Partners closed its fourth fund just above target on USD 2.9bn. One-third of the corpus has already been deployed
China RNA vaccine developer raises $42m
Therorna, a China-based biotech company specializing in vaccines and drugs based on circular RNA technology, has raised USD 42m in Series A funding.
China bio-manufacturing start-up Mojia raises $80m
Temasek Holdings has led a USD 80m Series B round for Shanghai-based bio-manufacturing start-up Mojia Biotech.
5Y leads $74m round for China AI drug developer
Beijing-based HeliXon, an artificial intelligence-enabled developer of protein-based drugs, has raised CNY 500m (USD 75m) in Series A funding led by 5Y Capital. Other investors include Gaorong Capital and Neumann Capital.
China fashion software platform Linctex raises $100m
Linctex Digital, a Shanghai-based design services platform for the fashion industry, has raised an extended pre-Series B round of nearly USD 100m from GL Ventures and CDH Investments.
China's ZWC hits first close on debut renminbi fund
Chinese venture capital firm ZWC Partners has reached the first close of CNY 1bn (USD 149m) on its debut renminbi-denominated fund. The overall target is CNY 1.5bn.
Deal focus: TH Capital identifies key niche in energy storage
Zhongchu Guoneng Technology is leading China’s push into compressed air energy storage as a means of harnessing fast-rising yet unstable wind and solar capacity. Tsinghua Holdings Capital is among the backers
LP interview: Hywin Holdings
US-listed Hywin Holdings is plugging China’s rich into private asset classes one handshake at a time despite increasing digitisation in this wealth migration theme. PE is a fast-growing slice of the pie
Capital Today leads $40m Series B for China's XYZ Robotics
XYZ Robotics, a Chinese start-up specialising in robotic hand-eye coordination, has raised an extended Series B round of USD 40m led by Capital Today China Group.
Hillhouse reaches first close on China carbon neutrality fund
Hillhouse Capital has reached the first close on its debut renminbi-denominated carbon neutrality fund, which has an overall target of around CNY 4bn (USD 597m).
Legend axes consumer from latest China TMT fund
Legend Capital has excluded the consumer-facing segment from its latest China technology, media, and telecom (TMT) fund, reflecting a broader sense of uncertainty among local managers regarding the regulatory environment.
China life sciences research business gets $300m Series C
MegaRobo Technologies, a China-based provider of artificial intelligence (AI) and robotics-enabled research services to the life sciences industry, has raised USD 300m in Series C funding.
